IP Library Granted Patent US 10,314,804
Granted Patent B2
US 10,314,804 · App. 15/570,720 · Granted Jun 11, 2019

Composition containing norbixin for protecting cells of the retinal pigment epithelium

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,314,804
App. No.
15/570,720
Granted
Jun 11, 2019
Kind
B2
Abstract

A method of photoprotecting cells of the retinal pigment epithelium (EPR) in mammals using a composition having norbixin. The norbixin is produced by purification from an extract of Bixa orellana seeds.

Claims (11)

1. A method of photoprotecting cells of a retinal pigment epithelium (RPE) in mammals comprising administering to a mammal a composition comprising norbixin obtained by purification from an extract of Bixa orellana seeds, per day, in an amount of between 0.48 mg/kg of body weight and 48 mg/kg of body weight.

2. The method as claimed in claim 1 , wherein the composition comprises more than 95% by weight of norbixin.

3. The method as claimed in claim 1 , wherein the composition comprises more than 90% by weight of norbixin in its 9′-cis form of formula (I):

4. The method as claimed in claim 1 , wherein the composition comprises at least one element chosen from zinc, vitamin C and vitamin E.

5. The method as claimed in claim 1 , wherein the composition is in the form of a food supplement or of a medicament.

6. The method as claimed in claim 1 , wherein the composition comprises a support acceptable for being ingested, injected in the eye, injected systemically or injected into the blood.

7. The method as claimed in claim 1 , wherein the composition is administered to prevent damage to a retina caused by exposure to a blue radiation corresponding to a blue band of a visible light spectrum, having a wavelength of between 435 nm and 490 nm.

8. The method as claimed in claim 1 , wherein the composition is administered to treat age-related macular degeneration (ARMD) in mammals.

9. The method as claimed in claim 1 , wherein the composition is administered to treat at least one of Stargardt disease and retinitis pigmentosa in mammals.

10. The method as claimed in claim 2 , comprising more than 90% by weight of norbixin in its 9′-cis form of formula (I):

11. The method as claimed in claim 1 , wherein the administered amount of the composition to the mammal, per day, is between 0.6 mg/kg of body weight and 20 mg/kg of body weight.

Assignments (3)
LIEN Recorded Aug 28, 2025
From: BIOPHYTIS S.A.
To: KREOS CAPITAL VI (UK) LIMITED
Reel/Frame 072710/0583 →
MERGER Recorded Apr 17, 2019
From: UNIVERSITÉ PARIS 6 PIERRE ET MARIE CURIE
To: SORBONNE UNVERSITÉ
Reel/Frame 048916/0888 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 22, 2018
From: LAFONT, RENE; VEILLET, STANISLAS; SAHEL, JOSE-ALAIN; FONTAINE, VALERIE; ELENA, PIERRE-PAUL
To: BIOPHYTIS; UNIVERSITE PARIS 6 PIERRE ET MARIE CURIE
Reel/Frame 047129/0126 →